MangoRx Launches Direct-To-Clinics Sales Division to Drive and Fuel Customer Acquisition and Revenue Growth
20. Februar 2024 09:00 ET
|
Mangoceuticals, Inc.
Newly developed clinic prescribing system will allow Doctors to prescribe MangoRx products from within practices and clinics Dallas, Texas, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc....
MangoRx Accepting Pre Orders for its “PRIME”, by MangoRx, Powered by Kyzatrex®️ FDA Approved Oral Testosterone Replacement Therapy (TRT) Product
05. Februar 2024 08:50 ET
|
Mangoceuticals, Inc.
The Dallas Based, Direct-to-Consumer Telemedicine Company to Offer 2 Months of Free ‘PRIME’ by MangoRx, Powered by Kyzatrex®️ (a $498 value) for First 1,000 Subscribers Dallas, Texas,...
Clarus Therapeutics Announces Closing of Upsized $30.0 Million Underwritten Public Offering
27. April 2022 13:43 ET
|
Clarus Therapeutics Holdings, Inc.
NORTHBROOK, Ill., April 27, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by...
Spartan Medical Associates Open New Location in Charlotte NC, Treating Men and Women with Hormone Replacement Therapy and TRT
15. März 2022 10:00 ET
|
Spartan Medical Associates, PC
Charlotte, March 15, 2022 (GLOBE NEWSWIRE) -- Leading hormone replacement specialists Spartan Medical Associates, who are based in North Carolina, have today announced the opening of a new treatment...
Clarus Therapeutics to Present at the Oppenheimer 32nd Annual Healthcare Conference
10. März 2022 09:05 ET
|
Clarus Therapeutics Holdings, Inc.
NORTHBROOK, Ill., March 10, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by...
Clarus Therapeutics Appoints Dr. Zhanna Jumadilova as Chief Clinical Development Officer
18. Januar 2022 09:05 ET
|
Clarus Therapeutics Holdings, Inc.
Dr. Jumadilova most recently led clinical development programs at Insmed and Pfizer and has nearly 30 years of combined pharmaceutical and biotech experience NORTHBROOK, Ill., Jan. 18, 2022 (GLOBE...
Clarus Therapeutics Reports Third Quarter 2021 Financial and Operating Results
18. November 2021 16:05 ET
|
Clarus Therapeutics Holdings, Inc.
Third quarter 2021 revenue increased 93% year-over-year to $4.3 million Third quarter 2021 total prescription growth for JATENZO® increased 12% sequentially and 132% year-over-year Conference call...
Clarus Therapeutics to Present New Real-World Experience Data for JATENZO® (testosterone undecanoate) at the 22nd Annual Fall Scientific Meeting of SMSNA
14. Oktober 2021 09:05 ET
|
Clarus Therapeutics Holdings, Inc.
JATENZO® (testosterone undecanoate) is the first and only FDA-approved oral softgel for testosterone replacement therapy (TRT) in adult males who have deficient testosterone due to certain medical...
Steroids for sale - the dangers TRT patients are facing to avoid high cost prescriptions
25. März 2021 13:00 ET
|
Secrets Of Bodybuilding
LOS ANGELES, March 25, 2021 (GLOBE NEWSWIRE) -- Secrets Of Bodybuilding - TRT (Testosterone Replacement Therapy) has massively grown in popularity over the last six years giving many patients back...
Clarus Therapeutics Announces Commercial Launch and Availability of JATENZO® (testosterone undecanoate) capsules, CIII for the Treatment of Hypogonadism
10. Februar 2020 08:00 ET
|
Clarus Therapeutics, Inc.
First and only FDA-approved oral treatment of its kind for testosterone deficiency1,2 NORTHBROOK, Ill., Feb. 10, 2020 (GLOBE NEWSWIRE) -- Clarus Therapeutics, Inc. today announced that JATENZO®...